Ovarian Reserve and Ankylosing Spondylitis

Overview

The aim of this study was to determine the status of ovarian reserve in patients with ankylosing spondylitis (AS) using anti-mullerian hormone (AMH) level and antral follicle count (AFC). Women with AS and women controls diagnosed according to the classification criteria proposed by the American-European Consensus Group will be included in the study. Ovarian reserve will be evaluated in terms of clinical findings, AFC and serum AMH and reproductive hormone levels. Researchers predict that the ovarian reserve may be reduced in patients with AS due to the autoimmune process and the pathophysiology of the disease. Serum AMH and ovarian AFC may be useful for assessing ovarian reserve. It is aimed to determine the course of ovarian reserve abnormalities and the best possible biomarkers of reduced ovarian reserve in patients with AS.

Full Title of Study: “Evaluation of Ovarian Reserve Using Anti-müllerian Hormone and Antral Follicle Count in Ankylosing Spondylitis: Preliminary Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 19, 2020

Interventions

  • Other: ovarian reserve for Ankylosing spondylitis and control groups
    • Additional organ diseases due to the pathophysiology of the disease may be seen in women with ankylosing spondylitis. therefore, we established the first group of women with the diagnosis of ankylosing spondylitis. Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. and health women will be control group. Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women. Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded.

Arms, Groups and Cohorts

  • Patients with Ankylosing spondylitis
    • Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women.In order to evaluate the ovarian reserve of the patients, the parameters we routinely look at will be evaluated as follows. the results of these tests will be observed. Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded.
  • Healthy women as controls
    • Regular menstruation with intervals of 21-35 days; cycle length variations <4 days; and both ovaries still present healthy women will create the control group.In order to evaluate the ovarian reserve of the patients, the parameters we routinely look at will be evaluated as follows. the results of these tests will be observed. Amh will be looked for. (pmol / l). Antral folukul census in the overin folukular stage will be valued as number. Fsh (iu / l) and Estradiol (pmol / l) values will also be recorded.

Clinical Trial Outcome Measures

Primary Measures

  • anti-müllerian hormone (AMH)
    • Time Frame: 3 days
    • For ovarian capacity AMH will be examined and AMH levels will be recorded in pmol/l
  • antral follicle count (AFC)
    • Time Frame: 1 day
    • For ovarian capacity AFC will be examined and It will be recorded as a NUMBER.

Participating in This Clinical Trial

Inclusion Criteria

  • regular menstruation with intervals of 21-35 days; – cycle length variations <4 days; – both ovaries still present Exclusion Criteria:

  • history of liver failure; – diagnosed malignancy; – cigarette smoking; – chronic renal failure; – known infertility; – presence of gynecological abnormalities such as abnormal uterine bleeding or menorrhagia; – history of ovarian surgery; – history of hormone preparation (including corticosteroids) use or use of herbal products within 3 months; – diagnosis of polycystic ovary syndrome.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Kanuni Sultan Suleyman Training and Research Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Pınar Kadirogulları, Principal investigator, Pınar kadirogullari, M.D, Department of Obstetrics and Gynecology – Kanuni Sultan Suleyman Training and Research Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.